Seattle startup wants to be the Amazon of primary care

Amy Baxter | | Health Exec | Precision Medicine

A Seattle-based startup, 98point6, is looking to become the Amazon of primary care, according to a profile by CNBC. The company has already raised $86 million and runs a subscription-based model that aims to connect consumers with primary care doctors.

The company even has a former Amazon Prime executive, Rob Schwietzer, as its product leader.

For $20 for an introductory year, consumers can message with doctors with no additional fees for a visit. The company is betting on consumers’ growing attachment to technology, as well as needed disruption in the healthcare space.

See the full story below:

Seattle start-up is building the Amazon Prime of primary care with $86 million …

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.